Tenax Therapeutics, Inc.: Form 10-Q for the period ended Oct 31, 2014
Filed with the SEC on Dec 15, 2014 and accepted by EDGAR at Dec 15, 2014, 16:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-08-01 to 2014-10-31 | $0 | us-gaap:Revenues |
| Revenue | 6 months2014-05-01 to 2014-10-31 | $0 | us-gaap:Revenues |
| Cost of revenue | 3 months2014-08-01 to 2014-10-31 | $0 | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2014-05-01 to 2014-10-31 | $0 | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2014-08-01 to 2014-10-31 | $0 | us-gaap:GrossProfit |
| Gross profit | 6 months2014-05-01 to 2014-10-31 | $0 | us-gaap:GrossProfit |
| Research and development | 3 months2014-08-01 to 2014-10-31 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2014-05-01 to 2014-10-31 | $3.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2014-08-01 to 2014-10-31 | $1.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2014-05-01 to 2014-10-31 | $3.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2014-08-01 to 2014-10-31 | −$4.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2014-05-01 to 2014-10-31 | −$6.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-08-01 to 2014-10-31 | $59 | us-gaap:InterestExpense |
| Interest expense | 6 months2014-05-01 to 2014-10-31 | $46.3k | us-gaap:InterestExpense |
| Net income | 3 months2014-08-01 to 2014-10-31 | −$4.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2014-05-01 to 2014-10-31 | −$6.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-08-01 to 2014-10-31 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2014-05-01 to 2014-10-31 | −$0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-08-01 to 2014-10-31 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2014-05-01 to 2014-10-31 | −$0.22 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-08-01 to 2014-10-31 | 28,107,395 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2014-05-01 to 2014-10-31 | 28,037,204 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2014-05-01 to 2014-10-31 | −$4.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2014-05-01 to 2014-10-31 | $41.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-10-31 | $14.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-10-31 | $23.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-10-31 | $89.2m | us-gaap:Assets |
| Current liabilities | At period end2014-10-31 | $3.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-10-31 | $11.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-10-31 | $77.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001354488-14-006182. Last ingested by Listed: Oct 27, 2026, 17:29 ET. Listed shows no prices and gives no investment advice.